G
G

GoldmSachs

Technical Summary

IndicatorValueTrend
IndicatorValueTrend
IndicatorValueTrend
IndicatorS3S2S1PR1R2R3

News

China's markets regulator talks to banks to calm jitters - sources

HONG KONG, July 29 (Reuters) - China's securities regulator on Wednesday night held a meeting with executives of top global investment banks with an aim to calm financial markets nerves, people familiar with the matter told Reuters. The online meeting adds to official efforts to shore up investor confidence in Chinese markets, which has been dented
C
G
J
U

Goldman's China JV gets regulatory nod for alternative investment business

BEIJING, July 28 (Reuters) - Goldman Sachs' China securities venture obtained approval from the Chinese securities watchdog on Wednesday to conduct alternative investment business via a subsidiary. The China Securities Regulatory Commission said Goldman Sachs Gao Hua Securities Co should strengthen its risk control over its subsidiary and prevent a
G

Credit Suisse hires Goldman Sachs partner to lead risk turnaround

* Credit Suisse taps Goldman ranks for a second time * Wildermuth to join by February 2022 at the latest * Tighter risk management a key priority By Brenna Hughes Neghaiwi ZURICH, July 27 (Reuters) - Credit Suisse CSGN.S on Tuesday appointed Goldman Sachs GS.N partner David Wildermuth its new chief risk officer, as it seeks to turn the corner on th
C
G

Credit Suisse appoints Goldman Sachs' Wildermuth to lead risk turnaround

ZURICH, July 27 (Reuters) - Credit Suisse CSGN.S on Tuesday appointed Goldman Sachs' GS.N David Wildermuth as its new chief risk officer, as it seeks to turn the corner on the Archegos and Greensill scandals that have rocked Switzerland's second-biggest bank. "I am delighted to welcome David to Credit Suisse, where he will help shape the Group's en
C
G

Brazilian oncology chain Oncoclinicas files for $670 million IPO

SAO PAULO, July 20 (Reuters) - Brazilian oncology clinics chain Oncoclinicas, which is backed by Goldman Sachs Group Inc GS.N , plans to raise roughly 3.5 billion reais ($671.26 million) in an initial public offering, amid a dealmaking boom in the healthcare sector in the country. Oncoclinicas set its price per share at between 22.21 reais and 30.2
C
G
J
I

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

We are using cookies to give you the best experience on our website. Read more or change your cookie settings.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.